J B Chemicals and Pharmaceuticals

J B Chemicals and Pharmaceuticals

1,687.60
+2.80
(0.17%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
26,292.80 Cr
EPS
42.45
PE Ratio
41.12
Dividend Yield
0.92 %
Industry
Healthcare
52 Week High
2,030.00
52 Week Low
1,385.75
PB Ratio
7.66
Debt to Equity
0.06
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+90.91 %
+90.91 %
Hold
Hold+9.09 %
+9.09 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,678.00
#1 4,06,039.50
35.43
#1 54,729.00
12.06
#1 10,980
-18.99
48.02
6,613.00
1,77,545.40
81.09
9,712.00
0.89
2,191
23.05
41.67
3,503.50
1,19,268.20
62.27
11,539.40
11.59
1,911
10.91
67.44
1,464.40
1,19,048.10
23.16
28,409.50
7.12
5,291
30.28
38.07
2,670.50
1,09,208.00
62.91
12,744.20
19.57
2,007
-10.91
70.32
1,240.00
1,05,097.50
#1 18.95
33,741.20
12.36
5,725
21.14
36.94
956.75
97,604.70
20.99
23,511.00
13.82
4,615
-0.19
43.23
1,903.20
87,731.20
26.74
22,192.10
#1 19.94
3,024
#1 112.49
41.78
34,130.00
72,428.20
51.15
6,684.70
10.80
1,414
27.83
57.31
1,101.40
66,124.30
19.14
31,378.10
17.55
3,366
-0.50
38.68

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
11.46 %
Net Income Growth
34.78 %
Cash Flow Change
12.72 %
ROE
14.34 %
ROCE
29.17 %
EBITDA Margin (Avg.)
18.76 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
408
444
398
435
459
475
445
447
545
452
604
554
619
613
605
627
786
811
796
767
902
889
852
878
1,010
1,011
972
964
Expenses
326
354
304
353
350
356
339
362
367
334
377
405
442
466
473
500
612
625
618
599
664
638
621
664
724
730
709
723
EBITDA
82
90
94
81
109
119
106
85
178
119
227
149
177
146
133
127
174
186
178
168
238
251
231
215
286
281
263
241
Operating Profit %
20 %
19 %
20 %
16 %
22 %
22 %
21 %
18 %
30 %
25 %
31 %
23 %
27 %
21 %
21 %
20 %
22 %
23 %
22 %
21 %
26 %
28 %
26 %
23 %
28 %
27 %
26 %
24 %
Depreciation
15
15
15
12
16
16
17
17
17
18
17
17
18
16
17
22
26
28
28
32
31
32
34
41
41
42
42
46
Interest
1
1
1
1
1
1
1
1
4
2
1
1
1
1
1
2
6
8
8
14
12
10
13
9
6
2
3
2
Profit Before Tax
66
75
78
68
92
102
88
67
157
99
209
132
158
129
114
103
142
150
141
123
194
209
184
165
240
237
218
193
Tax
21
23
28
22
30
8
22
17
38
25
54
31
39
32
30
18
37
39
35
35
52
58
50
38
63
62
56
47
Net Profit
46
52
50
47
62
94
66
50
120
74
154
101
119
98
84
85
105
111
106
88
142
151
134
126
177
175
163
146
EPS in ₹
5.46
6.14
6.07
5.68
7.73
11.67
8.26
6.30
15.45
9.55
19.94
13.02
15.38
12.65
10.85
10.98
13.59
14.37
13.72
11.33
9.20
9.72
8.62
8.22
11.39
11.24
10.46
9.36

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,487
1,648
1,674
1,765
1,792
1,821
2,238
2,607
3,554
3,994
4,274
Fixed Assets
329
440
679
640
621
651
634
1,277
1,901
2,004
1,968
Current Assets
901
816
795
1,047
1,051
1,073
1,553
1,253
1,528
1,853
1,923
Capital Work in Progress
55
135
4
17
15
16
26
19
55
76
63
Investments
367
479
411
434
457
403
678
13
206
388
345
Other Assets
737
594
580
674
699
750
901
1,299
1,392
1,525
1,897
Total Liabilities
1,487
1,648
1,674
1,765
1,792
1,821
2,238
2,607
3,554
3,994
4,274
Current Liabilities
460
431
281
275
244
313
345
384
554
868
632
Non Current Liabilities
33
31
27
46
65
69
79
85
519
203
208
Total Equity
995
1,186
1,366
1,444
1,483
1,438
1,813
2,139
2,480
2,923
3,433
Reserve & Surplus
978
1,167
1,347
1,425
1,464
1,420
1,794
2,119
2,465
2,908
3,418
Share Capital
17
17
17
17
16
16
16
16
16
16
16

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
13
15
-28
43
11
-6
-3
34
20
11
27
Investing Activities
-112
-26
-45
-21
-28
24
-231
2
-962
-404
-296
Operating Activities
127
140
201
123
194
276
315
170
626
801
903
Financing Activities
-1
-100
-184
-60
-156
-306
-87
-138
357
-386
-580

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
55.91 %
55.91 %
55.91 %
54.00 %
54.00 %
54.00 %
53.96 %
53.95 %
53.93 %
53.91 %
53.86 %
53.83 %
53.78 %
53.77 %
53.74 %
53.66 %
47.84 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.05 %
0.00 %
11.06 %
12.17 %
13.63 %
14.64 %
18.30 %
DIIs
12.41 %
12.32 %
14.76 %
16.03 %
16.67 %
17.52 %
18.08 %
18.54 %
19.08 %
18.65 %
18.58 %
17.97 %
18.38 %
17.62 %
16.81 %
16.41 %
18.72 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.01 %
0.00 %
0.00 %
Public / Retail
20.50 %
19.69 %
17.64 %
18.38 %
17.87 %
17.37 %
16.94 %
16.70 %
15.98 %
15.66 %
15.34 %
15.17 %
14.69 %
14.38 %
13.87 %
13.42 %
13.28 %
Others
11.18 %
12.08 %
11.70 %
11.58 %
11.47 %
11.10 %
11.02 %
10.81 %
11.00 %
11.79 %
2.17 %
13.03 %
2.09 %
2.05 %
1.94 %
1.87 %
1.86 %
No of Share Holders
0
65,715
70,740
71,788
64,861
61,314
60,268
58,629
56,633
55,965
60,817
63,230
63,892
66,953
62,743
62,081
63,948

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 5 1 2 5 11 16.5 16.5 17.75 12.25 15.5
Dividend Yield (%) 2.89 0.64 1.1 1.96 1.75 2.1 1.67 1.08 0.75 0.92

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
06 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
06 Aug 2025 1,612.55 1,684.80
30 Jul 2025 DIVIDEND Dividend
₹ 7.00 /share
30 Jul 2025 1,579.85 1,684.80
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 1,658.70 1,579.85
08 Feb 2025 DIVIDEND Dividend
₹ 8.50 /share
07 Feb 2025 1,714.10 1,673.75
04 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Feb 2025 1,805.05 1,714.10
06 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2024 1,895.75 1,852.00
21 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
21 Aug 2024 1,788.80 1,942.60
14 Aug 2024 DIVIDEND Dividend
₹ 6.75 /share
14 Aug 2024 1,832.55 1,941.60
16 Feb 2024 DIVIDEND Dividend
₹ 5.50 /share
16 Feb 2024 1,708.40 1,664.30
24 May 2023 SPLIT Split
1:2
18 Sept 2023 976.00 976.00
17 Aug 2023 DIVIDEND Dividend
₹ 9.25 /share
17 Aug 2023 976.00 1,315.08
18 Feb 2023 DIVIDEND Dividend
₹ 8.50 /share
17 Feb 2023 1,008.50 982.73
17 Aug 2022 DIVIDEND Dividend
₹ 8.00 /share
12 Aug 2022 785.18 931.68
24 Feb 2022 DIVIDEND Dividend
₹ 8.50 /share
23 Feb 2022 852.88 804.93
02 Sept 2021 DIVIDEND Dividend
₹ 8.00 /share
01 Sept 2021 770.03 850.15
22 Feb 2021 DIVIDEND Dividend
₹ 8.50 /share
18 Feb 2021 520.90 555.25

Announcements

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS4 hours ago
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended On June 30 20251 day ago
Letter To Shareholders - Integrated Annual Report5 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20185 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Draft Letter of Offer10 days ago
Business Responsibility and Sustainability Reporting (BRSR)Jul 11, 2025
Intimation Of Record DateJul 11, 2025
Reg. 34 (1) Annual Report.Jul 11, 2025
Notice Of Annual General MeetingJul 11, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Updates on Open OfferJul 04, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 30, 2025
Public AnnouncementJun 30, 2025
Announcement under Regulation 30 (LODR)-Public Announcement-Open OfferJun 30, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 29, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJun 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 29, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJun 28, 2025
Closure of Trading WindowJun 27, 2025
ANDA Approval By US FDAJun 26, 2025
ANDA Approval By US FDAJun 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 11, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AMay 14, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 14, 2025
Appointment Of Secretarial AuditorMay 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 14, 2025
Corporate Action-Board approves DividendMay 14, 2025
Audited Standalone & Consolidated Financial Results For The Year Ended On March 31 2025May 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Year Ended On March 31 2025 Accompanied By Auditors Report.May 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 14, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 23, 2025
Board Meeting Intimation for (I) Consideration And Approval Of The Audited Financial Results For The Quarter And Year Ended On March 31 2025; And (Ii) Consideration And Recommendation Of Dividend On Equity Shares Of The Company If Any Subject To ApprovaApr 22, 2025
ANDA Approval By US FDAApr 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025

Technical Indicators

RSI(14)
Neutral
52.83
ATR(14)
Less Volatile
38.67
STOCH(9,6)
Overbought
84.26
STOCH RSI(14)
Overbought
94.62
MACD(12,26)
Bullish
3.37
ADX(14)
Weak Trend
17.01
UO(9)
Bearish
65.66
ROC(12)
Uptrend And Accelerating
2.77
WillR(14)
Overbought
-7.61

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Union Small Cap Fund Direct-Growth
1.76%
-80996
-0.96%
-1.05%
Union Midcap Fund Direct - Growth
0.60%
54513
0.60%
0.60%
Bandhan Small Cap Fund Direct-Growth
0.16%
-41723
-0.08%
-0.12%
LIC MF Focused Fund Direct - Growth
3.01%
26047
2.47%
3.01%
Canara Robeco ELSS Tax Saver Direct- Growth
0.90%
25000
0.03%
0.03%
Bandhan Multi Asset Allocation Fund Direct-Growth
0.00%
-25000
-0.22%
-0.22%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
0.53%
20000
0.53%
0.53%
Axis Equity Savings Fund Direct-Growth
0.49%
16000
0.28%
0.49%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.65%
-15400
-0.08%
-0.11%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.67%
13559
0.04%
0.01%
LIC MF Manufacturing Fund Direct-Growth
0.65%
10311
0.19%
0.16%
Motilal Oswal Quant Fund Direct-Growth
0.97%
8534
0.97%
0.97%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.67%
7444
0.04%
0.00%
Groww Multicap Fund Direct-Growth
0.00%
-7364
-1.18%
-1.29%
WhiteOak Capital Special Opportunities Fund Direct - Growth
1.06%
5811
0.00%
-0.29%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.67%
4508
0.04%
0.01%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
2.25%
4207
0.05%
-0.09%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.67%
3390
0.04%
0.00%
Nippon India Small Cap Fund Direct- Growth
0.25%
3235
-0.01%
-0.01%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.67%
2855
0.04%
0.01%
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth
2.30%
2652
0.13%
0.20%
Mirae Asset Small Cap Fund Direct-Growth
1.23%
1830
-0.14%
-0.27%
ICICI Prudential Nifty Pharma Index Fund Direct - Growth
1.72%
1443
0.14%
0.23%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.07%
1231
0.01%
0.01%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.68%
860
0.05%
0.01%

About J B Chemicals and Pharmaceuticals

J.B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1976. It manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. The company specializes in gastroenterology, hypertension, and dermatology, with additional focus on nephrology, respiratory, virology, diabetes, and nicotine replacement therapy. Key brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has manufacturing facilities in various locations in India and maintains a direct presence in Russia and South Africa, with distributor relationships in the US and other international markets. In 2020, Tau Investment Holdings Pte. Ltd., an affiliate of KKR, acquired a controlling stake in the company. J.B. Chemicals & Pharmaceuticals continues to expand its product portfolio through new launches and acquisitions in various therapeutic segments.
Chairperson NameArun Duggal